Pathologic deregulation of IGF1R gene expression as a result of tumor-specific, loss-of-function p53 mutations may lead to increased cell surface IGF1R concentrations, with ensuing enhancement of receptor phosphorylation by endocrine or locally-produced IGF1 or IGF2 [41, 42]. Here, IGF1 is linked to neoplasm.